FDA questions role of payments in Zimmer Dynesys study |

FDA questions role of payments in Zimmer Dynesys study

 

Most patients in the trial were treated by surgeons who had received consulting payments from Warsaw, Ind.-based Zimmer. More than half of the patients in the trial were treated at medical centers that reported more than $100,000 in payments from the company, according to FDA’s review.

The FDA said one analysis of the company’s results showed a positive relationship between financial payments and clinical success for the device.

http://ow.ly/yQek

Leave a Reply

Your email address will not be published. Required fields are marked *